Robert E. Landry - Dec 27, 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Stock symbol
REGN
Transactions as of
Dec 27, 2023
Transactions value $
-$407,916
Form type
4
Date filed
12/29/2023, 04:05 PM
Previous filing
Dec 14, 2023
Next filing
Jan 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $284K +750 +3.51% $378.98* 22.1K Dec 27, 2023 Direct
transaction REGN Common Stock Tax liability -$473K -542 -2.45% $872.21 21.6K Dec 27, 2023 Direct
transaction REGN Common Stock Options Exercise $322K +850 +3.94% $378.98* 22.4K Dec 28, 2023 Direct
transaction REGN Common Stock Tax liability -$542K -612 -2.73% $884.88 21.8K Dec 28, 2023 Direct
holding REGN Common Stock 270 Dec 27, 2023 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -750 -3.88% $0.00 18.6K Dec 27, 2023 Common Stock 750 $378.98 Direct F1
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -850 -4.57% $0.00 17.7K Dec 28, 2023 Common Stock 850 $378.98 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award vests in four equal annual installments, commencing one year after the date of grant.